S1021 MELD-Na Score Prognostic Utility and Implementation in Clinically Relevant Outcomes of Patients With SARS-CoV-2

Stawinski, Peter; Dziadkowiec, Karolina N.; Dewaswala, Nakeya; Suarez, Laura; Simms, Larnelle N.; Abbasi, Baher Al; Aboulenain, Samar; Abdallah, Ahmed; Gupta, Kapil; Ramos, Fergie; Pino, Jesus; Almeida, K. De

doi:10.14309/01.ajg.0000706132.93288.ef

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been hypothesized earlier in the pandemic that patients taking ACE inhibitors or angiotensin receptor blockers would be at a higher risk of adverse clinical outcomes; however, later studies have refuted this hypothesis [17,18]. In addition, COVID-19 is associated with myocardial injury [19,20], thrombocytopenia [21,22], and liver dysfunction [23][24][25][26][27] which predicts higher mortality in the general population and in patients with HF [28,29].…”

Section: Discussionmentioning

confidence: 99%

Outcomes of Heart Failure in COVID-19 Patients: An Appalachian Experience

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background The Southeastern rural areas of the USA have a higher prevalence of heart failure (HF). Coronavirus disease 2019 (COVID-19) infection is associated with poor outcomes in patients with HF. Our study aimed to compare the outcomes of hospitalized HF patients with and without COVID-19 infection specifically in rural parts of the USA. Methods We conducted a retrospective cohort study of HF patients with and without COVID-19 hospitalized in Southeastern rural parts of the USA by using the Appalachian Regional Healthcare System. Analyses were stratified by waves from April 1, 2020 to May 31, 2021, and from June 1, 2021 to October 19, 2021. Results Of the 14,379 patients hospitalized with HF, 6% had concomitant COVID-19 infection. We found that HF patients with COVID-19 had higher mortality rate compared to those without COVID-19 (21.8% versus 3.8%, respectively, P < 0.01). Additionally, hospital resource utilization was significantly higher in HF patients with COVID-19 compared to HF patients without COVID-19 with intensive care unit (ICU) utilization of 21.6% versus 13.8%, P < 0.01, mechanical ventilation use of 17.3% versus 6.2%, P < 0.01, and vasopressor/inotrope use of 16.8% versus 7.9%, P < 0.01. A lower percentage of those with COVID-19 were discharged home compared to those without a COVID-19 diagnosis (63.4% versus 72.0%, respectively). There was a six-fold greater odds of dying in the first wave and seven-fold greater odds of dying in the second wave. Conclusions Our study confirms previous findings of poor outcome in HF patients with COVID-19. There is a need for review of healthcare resources in rural hospitals which already face numerous healthcare challenges.

show abstract